OS Therapies (OSTX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

OSTX OS Therapies

Watchlist

2.850
+0.041+1.47%

Close Nov 8 16:00 ET

2.850
0.0000.00%

Post 20:01 ET

59.52MMarket Cap-9076P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

OS Therapies to Present at The Spartan Capital Investor Conference
Yahoo FinanceNov 4 07:00 ET
Join OS Therapies' Exclusive Live Investor Webinar and Q&A Session on October 30
BusinesswireOct 30 08:51 ET
Express News | Os Therapies: Colin Goddard Notified Board of His Resignation as Chairman of Board
ReutersOct 28 16:59 ET
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
BusinesswireOct 28 16:44 ET
Express News | Os Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
ReutersOct 28 16:44 ET
Catalyst Watch: Eyes on Tech With Apple, Amazon, Alphabet, and Meta Reporting
Seeking AlphaOct 25 15:00 ET

Comments

Jaguar8

Sep 11 07:18

NEWS

$OS Therapies (OSTX.US)$
OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models
Folate receptor alpha targeting drug conjugate & hexa silanol exatecan (FRA-H) payloads tested in animal models of ovarian cancer
Strong efficacy for FRA-H in KB and IGROV-1 mouse models of ovarian cancer
Strong safety profile for FRA-H wit...

Jaguar8

Aug 29 06:53

NEWS

$OS Therapies (OSTX.US)$
OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose
OS Therapies Incorporated (NYSE:OSTX) ("OS Therapies" or "the Company"), an ADC and Immunotherapy research and clinical-stage biopharmaceutical company, today announced that the last patient (Patient #41) enrolled in the AOST-2121 clinical trial (NCT04974008) of OST-HER2 in recurred, resected Osteosarcoma (OS) - has received its last treatment dos...